Trials involving Multiple Types of Cancer

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(Merck) MK-3475-587 / KEYNOTE 587A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab TrialMcWhirter, Dr ElaineOpen to recruitmentNCT03486873
(HHS) CRUSSHStereotactic body radiotherapy (SBRT) boost following urgent 3D conformal radiotherapy in the treatment of metastatic epidural spinal cord compression (SCC): A phase I feasibility trialDonovan, Dr ElysiaOpen to recruitmentNCT03529708
(IMV) Immunovac / P1719-SUR-Z11A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced and Recurrent Solid TumoursHirte, Dr HalOpen to recruitmentNCT03836352
(Tesaro) 4010-01-001 / GARNETA Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1
Monoclonal Antibody, in Patients with Advanced Solid Tumors
Elit, Dr LaurieOpen to recruitmentNCT02715284
(Ayala) AL-ACC-01 / ACCURACYA Phase 2, Open-Label, Single-Arm, Multi-Center Study Of AL101 (BMS-906024) In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch MutationsHotte, Dr SebastienOpen to recruitmentNCT03691207
(Debio) 1143-NSCLC-105A phase-Ib dose-finding study of the SMAC mimetic Debio 1143 when given in combination with the anti-PD-L1 antibody avelumab to patients with advanced solid malignancies and, in an expansion cohort, to patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) after platinum-based therapyJuergens, Dr RosalynOpen to recruitmentNCT03270176
(UHN) OCTANEOntario-wide Cancer TArgeted Nucleic acid Evaluation (OCTANE)Hotte, Dr SebastienSuspended/On holdNCT02906943
(CCTG) IND.238A Phase II Study of Durvalumab Retreatment in Patients who Discontinued Prior Checkpoint Therapy Due to Immune Related ToxicityEllis, Dr PeterSuspended/On holdNCT03847649
(AstraZeneca) D4191C00068 / STRONGAn Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG) – Core Protocol; Module A – Post-Chemotherapy Urothelial and NonUrothelial Carcinoma of the Urinary TractHotte, Dr SebastienSuspended/On holdNCT03084471
Download PDF